Itaphyte 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole exerts its antifungal effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Itaphyte 200 is indicated for the management of systemic and superficial mycoses, including blastomycosis, histoplasmosis, aspergillosis, and onychomycosis, as well as infections caused by dermatophytes and Candida species. The capsule formulation ensures optimal bioavailability and convenient oral administration. Itaphyte 200 should be used under medical supervision, with dosing adjusted according to the severity and type of infection. Caution is advised in patients with hepatic impairment, as itraconazole is metabolized primarily by the liver, and hepatotoxicity may occur. Common adverse effects include gastrointestinal disturbances, headache, and rash, while serious adverse reactions such as cardiac failure and liver toxicity are rare but require immediate medical attention. Drug interactions are significant due to itraconazole’s inhibition of cytochrome P450 enzymes; thus, concomitant use with certain medications should be carefully monitored or avoided. Itaphyte 200 provides an effective therapeutic option for fungal infections when used as directed by a healthcare professional.